Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern

Luca Murera, Romain Vollea, Varan Andriasyana, Anthony Petkidisa, Alfonso Gomez-Gonzaleza, Liliane Yanga, Nicole Meilia, Maarit Suomalainen, Michael Bauera, Daniela Policarpo Sequeiraa, Dominik Olszewskia, Fanny Georgia, Fabien Kuttlerb, Gerardo Turcattib, Urs F. Grebera,*

a Department of Molecular Life Sciences, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland
b Biomolecular Screening Facility, School of Life Sciences, Ecole Polytechnique Federale de Lausanne (EPFL), Station 15, 1015, Lausanne, Switzerland

ARTICLE INFO

Keywords:
Human coronavirus drug screen at single cell resolution in arrayed format
Human explant nasal and bronchial epithelial cells
Repurposing methylene blue
Mycophenolic acid
Posaconazole
Drug synergy in vitro
Post-entry coronavirus inhibition
SARS-CoV-2 variants of concern

ABSTRACT

Endemic human coronaviruses (hCoVs) 229E and OC43 cause respiratory disease with recurrent infections, while severe acute respiratory syndrome (SARS)-CoV-2 spreads across the world with impact on health and societies. Here, we report an image-based multicycle infection procedure with α-coronavirus hCoV-229E-eGFP in an arrayed chemical library screen of 5440 clinical and preclinical compounds. Toxicity counter selection and challenge with the β-coronaviruses OC43 and SARS-CoV-2 in tissue culture and human airway epithelial explant cultures (HAEEC) identified four FDA-approved compounds with oral availability. Methylene blue (MB, used for the treatment of methemoglobinemia), Mycophenolic acid (MPA, used in organ transplantation) and the anti-fungal agent Posaconazole (POS) had the broadest anti-CoV spectrum. They inhibited the shedding of SARS-CoV-2 and variants-of-concern (alpha, beta, gamma, delta) from HAEEC in either pre- or post exposure regimens at clinically relevant concentrations. Co-treatment of cultured cells with MB and the FDA-approved SARS-CoV-2 RNA-polymerase inhibitor Remdesivir reduced the effective anti-viral concentrations of MB by 2-fold, and Remdesivir by 4 to 10-fold, indicated by BLISS independence synergy modelling. Neither MB, nor MPA, nor POS affected the cell delivery of SARS-CoV-2 or OC43 (+)sense RNA, but blocked subsequent viral RNA accumulation in cells. Unlike Remdesivir, MB, MPA or POS did not reduce the release of viral RNA in post exposure regimen, thus indicating infection inhibition at a post-replicating step as well. In summary, the data emphasize the power of unbiased, full cycle compound screens to identify and repurpose broadly acting drugs against coronaviruses.

1. Introduction

In December 2019, a local outbreak of pneumonia caused by an unknown agent was reported in Wuhan (Hubei, China), and soon after the agent was identified as SARS-CoV-2 causing Coronavirus disease 2019 (COVID-19) (Wu et al., 2020). As of Jan 18, 2022, there were more than 330 million PCR positive cases and 5.5 million deaths related to SARS-CoV-2 related to SAT (computed by the Johns Hopkins Coronavirus Research Center)(Home). Although vaccinations with mRNA and viral vectors strongly attenuate the severity of SARS-CoV-2 caused disease (Baden et al., 2021; Voysey et al., 2021), evidence emerges that vaccination will not suffice to contain the ongoing pandemics, and incompletely protects humans from severe COVID-19 (Planas et al., 2021; Hacisuleyman et al., 2021; Micchova et al., 2021; Kreer et al., 2020; Creech et al., 2021). Infection breakthrough is in part associated with emerging SARS-CoV-2 variants. Variants of concern are more contagious (alpha variant B.1.1.7, and delta variant B.1.617.2), and exhibit reduced susceptibility to antibodies from vaccinated or recovered individuals (beta variant B.1.351, gamma variant P.1 derived from B.1.1.28, delta variant B.1.617.2). Notably, many of the mutations of concern are located in the spike glycoprotein of the SARS-CoV-2 variants.
Severe COVID-19 is accompanied by respiratory failure, and patients require mechanical ventilation at intensive care units, and are at risk to develop acute respiratory distress syndromes, multiple organ dysfunction syndromes or failures and death (Casella et al., 2021). Current treatment options are limited, and include supportive care, and administration of the viral RNA polymerase inhibitor Remdesivir together with corticosteroids (https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/). Besides the mRNA vaccines, there are five FDA approved anti-COVID-19 therapies - the repurposed viral polymerase inhibitor Remdesivir (Beigel et al., 2020a), the janus kinase (JAK) 1 and 2 inhibitor Baricitinib blocking proinflammatory syndrome, the anti-S-protein IgG monoclonal antibody LY-CoV555, the anti-SARS-CoV-2 antibody cocktail Casirivimab/Imdevimab, and the monoclonal antibody Acemtra blocking the interleukin 6 receptor (https://racetoacure.stanford.edu). Recently, the FDA emergency-use authorized Paxlovid, a SARS-CoV-2 3CL protease inhibitor, and Molnupiravir, an RNA mutagen for the virus. Currently, Remdesivir in combination with anti-inflammatory agents, such as the corticosteroid dexamethasone is a broadly used treatment to restrict severe lung inflammation and multiorgan failure upon marked immune cell dysregulation and cytokine storm syndrome (Neurath, 2021).

Drug repurposing allows for rapid identification of clinically approved or investigational compounds towards emerging indications. This approach offers a multitude of advantages over de novo drug development (reviewed in Ashburn and Thor, 2004). Most importantly, candidate compounds have a demonstrated safety record allowing for direct transition to human clinical trials. For example, the ReFrame library comprising some 12 000 compounds was used to screen single round SARS-CoV-2 infections, focussing on virus replication but omitting assembly and egress processes (Bakowski et al., 2021). This yielded compounds inhibiting genome replication and steps upstream of replication. Identified compounds included MK-4482 (Molnupiravir, nucleoside analog), Nafamostat mesylate (inhibitor of entry), hydroxyxyctydine (nucleoside analog), and nelfinavir, an HIV protease inhibitor also blocking human adenovirus infections (Georgi et al., 2020a). Other drugs proposed for repurposing against COVID-19 include the translation elongation inhibitor Aplidin (Pliitidespin) approved for the treatment of multiple myeloma (Riva et al., 2020; Losada et al., 2016; White et al., 2021), or the anti-viral anti-helminthic protophorone Niclosamide blocking endosomal low pH dependent viruses (Jurgit et al., 2012), as well as the anti-malaria agents Amodiaquine and Artesunate, the HIV protease inhibitor combination Lopinavir/Ritonavir, the RNA polymerase inhibitors Favipiravir and Ribavirin used to treat influenza virus and respiratory syncytial virus infections, respectively, the nucleoside analogue EIDD-2801 (MK-4482 or Molnupiravir), the influenza virus neuraminidase inhibitor Oselatamivir, and the SARS-CoV-2 Nsp12 RNA-polymerase inhibitor AT-527 (Good et al., 2021).

Here, we present the results from a multicycle drug repurposing screen which uncovers a range of drug candidates for COVID-19 treatment. Unlike canonical drug screens, our assay sampled the entire replication cycle of a GFP expressing variant of the endemic α-coronavirus hCoV-229E in the human hepatoma cell line Huh7. We validated the initial hits by two hCoVs, OC43 and SARS-CoV-2 in nasal and bronchial human airway epithelial explant cultures (HAEEC) grown at air-liquid interface, and identified 9 systemically useable compounds with broad coronavirus effects. Four of them are approved for human use, namely Methylene blue (MB, also known as Methylthioninium chloride), Mycophenolic acid (MPA), Posaconazole (POS), and R788 (Postamatinib), two are in phase II clinical trials (MLN4924, Ravanconazole), and three in preclinical tests (GPP-78, Ro 48–8071, SB-505124). One of the approved compounds (MPA) has anti-inflammatory effects in humans, and one (MB) has been widely used as a placebo control drug in clinical trials.

2. Methods

2.1. Viruses

hCoV-229E-GFP and SARS-CoV-2 “Wuhan” (TAR clone 3.3, München-1.1/2020/929) were obtained from Dr. Volker Thiel (University of Bern) (Cervantes-Barragan et al., 2010; Thao et al., 2020). SARS-CoV-2 Alpha (2 012 212 727 7D 15.01.21) and Beta (SDV4-SD1-4D 08/02/21) variants were obtained from Dr. Isabella Eckerle (University of Geneva). SARS-CoV-2 Gamma (NH-RIVM01915/2021) and Delta (NH-RIVM-27142/2021) variants were obtained from the RIVM (Netherlands) through European Virus Archive global. hCoV-229E-GFP was plaque purified and expanded on Huh7 cells for 48h. Supernatant was collected and cleared by centrifugation at 5000×g for 10 min. Human CoV-OC43 (ATCC-VR-1558) was obtained from LGC Standards Limited, (Tedddington, United Kingdom) and expanded as described above. Virus titers were determined by FFU titration according to GFP or immunofluorescence signal, and by TCID50 titration according to the Spearman–Kärber method. SARS-CoV-2 variants were checked by routine Sanger sequencing of the Spike glycoprotein (S-ORF nucleotide position: 20–800).

2.2. Cell lines

Huh7 and Vero E6 cells were obtained from Dr. Volker Thiel (University of Bern, Switzerland). Polyclonal Huh7-ACE2, HeLa-ACE2 and A549-ACE2 were generated by stable transfection with a lentiviral vector (pLVX-ACE2-RES-BSD). Parental HeLa and A549 cells were obtained from ATCC. The parental HeLa cell line additionally expressed an inducible eCas9 and a non-targeting ssRNA.

2.3. Cell culture

Huh7, Huh7-ACE2, HeLa-ACE2 and A549-ACE2 cells were maintained in Dulbecco’s Modified Eagle Medium (D6429; Sigma-Aldrich, St. Louis, USA) supplemented with 10% fetal bovine serum (FBS, 10270); Invitrogen, Carlsbad, USA), non-essential amino acids (M7145; Sigma-Aldrich, St. Louis, USA) supplemented with 10% fetal bovine serum. 

2.4. Compound library

The Prestwick chemical library (PCL) was purchased from Prestwick Chemical (Ilkirch, France). The remaining compounds were purchased from abcr GmbH, AK Scientific, Inc., Abcam plc., Acros Organics, Adipogen Life Sciences, Inc., Advanced ChemBlocks Inc., Alinda Chemical Trade Company Ltd., Angene, Apollo Scientific Ltd., Axon Medchem, BIOTREND Chemikalien GmbH, BLD Pharmatech Ltd., Biosynth Carbosynth, Cayman Chemical Company, ChemBridge Corporation, ChemDiv Inc., Chemodex Ltd., Cohesion Biosciences Ltd., Combi-Blocks, Inc., Enamine Ltd., Enzo Life Sciences Inc., Fluorochem Ltd., Focus Bio-molecules, InterBioScreen Ltd., J&K Scientific Ltd., Key Organics Ltds., LabSeeker, Inc, Life Chemicals Inc., Matrix Scientific, Maybridge Ltd., MedChemExpress, Merck KGaA, Otava Ltd., Pharmeks Ltd., Ramidus AB, SYNknase, Santa Cruz Biotechnology, Selleck Chemicals LLC, Sigma-Aldrich, Specs, Target Molecule Corp., Tocris Bioscience, Tokyo Chemical Industry, Toronto Research Chemicals, UkRorgSyntez Ltd., Vitas-M Laboratory Ltd. or Wuhan ChemFaces Biochemical Co., Ltd.. Compounds were dissolved in DMSO at a concentration of 10 mM.
2.5. High throughput compound screening

The screen was conducted in four completely independent biological replicates without technical replicates. For fluidics handling, a Matrix WellMate dispenser and Matrix WellMate tubing cartridges (Thermo Fisher Scientific, Waltham, USA), an Assist Plus pipetting robot (Integra Biosciences AG, Zizers, Switzerland) and an Echo acoustic dispenser (Labcyte Inc., Indiana, USA) were used. Compounds were spotted in random order at a 1.67 µM final concentration in microscopy grade 384-well plates (Perkin-Elmer, Waltham, USA), and frozen. Plates were bar-coded and shipped to University of Zurich without content lists to ensure blinding. Pre-spotted plates were thawed at room temperature 30 min prior to cell seeding. About 6000 HuH7 cells were seeded in 25 µl/well MEM +10% FCS and incubated at 37 °C, 5% CO2, 95% humidity overnight. Infection with hCoV-229E-GFP was performed by adding 50 focus forming units (FFU) per well in 5 µl and incubated at 33.5 °C, 5% CO2, 95% humidity for 48h. Finally, cells were Hoechst 33342 nuclear dye at 3 d pi. The experiment was performed in triplicate. The resulting plaques were quantified using Plaque 2.0 (Yakimovich et al., 2015b). The plaque number readout was normalized using the maximum number of plaques observed in the well of interest. The inhibitory effect of the drugs was represented as:

\[ \text{Inhibition}(\%) = \left( 1 - \frac{\text{Plaque Number}}{\max(\text{Plaque Number})} \right) \times 100 \]

Synergy of the drugs was assessed using BLISS synergy score calculated and visualized by using the web tool Synergy Finder (http://www.synergyfinder.org) (Zheng et al., 2021).

2.9. RNA FISH with branched DNA signal amplification

Fifteen thousand HuH7 wt or HuH7-Ace2 cells were seeded in a 96-well plate in the presence of Remdesivir (1 µM), POS (10 µM), MB (2 µM) or MPA (2 µM). On the following day, cells were inoculated with hCoV-OC43 or Sars-CoV-2 at 33.5 °C and 37 °C, respectively, for 2h with input virus amounts that resulted in about 15 uncoated genomes in the cells. Inocula were washed away, and cells incubated with fresh infection medium containing the compounds for 2, 8 or 24 h pi, fixed with 3% PFA in PBS for 30 min at RT, washed twice with PBS, dehydrated by subsequent incubation with 70%, 50% and 100% ethanol for 2 min at RT, and stored at −20 °C until staining. Samples were rehydrated by incubation with 70%, 50% and 100% ethanol and PBS for 2 min at RT. Rehydrated samples were FISH-stained against either OC43 or SARS-CoV-2 ORF1a mRNA using ViewRNA mRNA FISH assay with type 1 probe Alexa Fluor 546, according to the manufacturer’s instructions. Probes were custom made #6007025-01 and #6007037-01, respectively, directed against the SARS-CoV-2 ORF1a sequence. Subsequently, cells were stained with 40% 0.95 objective. For quantification, cells were segmented according to the DAPI and succinimidyl ester signals, and segment OC43 or SARS-CoV-2 (+) RNA dots assigned to single cells using CellProfiler.

2.10. Nasal and bronchial HAECC

Human nasal and bronchial airway tissue (MucilAir™, Epithelix SA, Geneva, Switzerland) cultured on transwell inserts (24-well plate) were maintained at air-liquid interface according to the supplier’s instructions and cell culture medium (EP05MM). The samples were mycoplasma-free based on acetate kinase or carbamate kinase activity measurements of the supplier. The bronchial HAECC were obtained from individual donors (Batch nr: MD0810) and the nasal HAECC from a pool of fourteen healthy donors (Batch nr: MP0009, and MP010). All donors were non-smokers. Movies of cilia beating were recorded at room temperatures with an inverted light microscope (Axiovert 135) at 100X magnification using CellF software (Olympus Soft Imaging Solutions GmbH, version 3.0).

2.11. SARS-CoV-2 infection of MucilAir™ tissue and drug treatment

Three days prior infection, MucilAir™ tissue apical surface were washed with 200 µl of warmed MucilAir™ culture medium at 37 °C for 20 min to homogenize the amount of mucus between inserts. Inserts were inoculated on the apical side with 1000 FFU of SARS-CoV-2 in a final volume of 100 µl at 37 °C for 2 h. Then the SARS-CoV-2 inoculum was removed and the apical surfaces quickly washed two-times with PBS. SARS-CoV-2 produced at the apical surface was collected at different

H1299 or HuH7 cells (about 20000 per well in a 96-well imaging plate) were treated with indicated concentrations of Remdesivir and MB at 37 °C, either alone and in combination resulting in a nine by nine matrix. After about 12h, the cells were infected with hCoV-229E-GFP virus at MOI 0.001 at 33.5 °C, fixed with 4% PFA and stained with Hoechst 33342 nuclear dye at 3 d pi. The experiment was performed in triplicate. The resulting plaques were quantified using Plaque 2.0 (Yakimovich et al., 2015b). The plaque number readout was normalized using the maximum number of plaques observed in the well of interest. The inhibitory effect of the drugs was represented as:

\[ \text{Inhibition}(\%) = \left( 1 - \frac{\text{Plaque Number}}{\max(\text{Plaque Number})} \right) \times 100 \]

Synergy of the drugs was assessed using BLISS synergy score calculated and visualized by using the web tool Synergy Finder (http://www.synergyfinder.org) (Zheng et al., 2021).
time point pi by 20 min apical wash and quantified in parallel by RT-qPCR and TCID50 titration with Vero E6 cells. Drug treatment was done at the indicated times pre and/or pi at indicated concentrations in fresh basolateral medium. Nasal and bronchial MucilAir™ tissue analysis was performed in duplicate.

2.12. Quantification of ciliary motion using optical flow

Transmitted light movies of ciliary beating were acquired at room temperature with an inverted light microscope (Axiovert 135) at 100x magnification using the cellIF software (Olympus Soft Imaging Solutions GmbH, version 3.0) during 20 s. Ciliary motion was assayed by computing the median of the TV-L1 norm of the optical flow (Zach et al., 2007), using a scikit-image implementation with the default parameters (van der Walt et al., 2014).

2.13. SARS-CoV-2 RNA quantification by real-time RT-qPCR

SARS-CoV-2 RNAs were extracted from samples with the Quick-RNA™ MiniprepPlus Kit (Zymo, R1058) after TRIzol™ reagent (Invitrogen, 15956026) treatment, according to the manufacturer’s instructions. The number of viral genome copies was evaluated by one-step real-time RT-qPCR of the SARS-CoV-2 M-gene with the Superscript TMIII Platinum One step Quantitative Kit (Invitrogen, 11732-020). Five RNA standards against their respective copy numbers in the range of 10³ to 10⁶ per μl yielding R² correlation coefficients of 0.9657 with inter-assay (n = 8) coefficients of variation ranging from 3.2 to 3.8%. The SARS-qRNAs were in vitro transcribed from a synthetic SARS-CoV-2 M-gene DNA template (Microsynth AG, Balgach Switzerland) under control of a T7 promoter by using the HiScribe™ T7 High Yield RNA Synthesis Kit (NEB, E2040). Then synthesized SARS-qRNAs were quantified with a NanoDrop spectrophotometer (Thermo Fisher Scientific). The oligonucleotides are presented in Table S1. We conducted PCR control measurements with comparable results using probes for either the M or the Po gene (Nsp12), the latter only present in genomic but not subgenomic RNA (Kim et al., 2020), thereby ruling out the possibility that the M probe would measure preferentially subgenomic RNA fragments (Table S2).

2.14. Key resources table
3. Replicates, statistics and randomization

Biological replicates of HAEEC experiments have been conducted with two independently prepared inserts followed by independent infection analyses. All drug inhibition experiments with HAEEC were repeated twice or three times with independent inserts at drug concentrations of 0.1, 1, 3.3, 5, 10 and 20 μM in post exposure regimen with essentially identical results. Randomization of donors for nasal HAEEC was achieved by pooling cells from 14 different donors, as described by the supplier (Epithelix SA, Geneva, Switzerland). Bronchial inserts were obtained from a single donor (Epithelix SA, Geneva, Switzerland). Further information about sample collection of biological data points and technical replicates is indicated in the corresponding figure legends.

4. Data sharing

The raw data of the screen are available under https://doi.org/10.1371/journal.pone.0138760

5. Role of the funding source

The funders had no impact on the design of the study, the collection, analyses or interpretation of data, the writing of the report or the publication strategy.

6. Ethics statement

Nasal polyp epithelial cells and bronchial epithelial cells were purchased from Epithelix SARL (Geneva, Switzerland). MucilAir™ cells were reconstituted from patients undergoing surgical nasal polypectomy or bronchial biopsies, respectively. All samples from Epithelix SARL were obtained with informed consent, according to the declaration of Helsinki on biomedical research (Hong Kong amendment, 1989), and received approval from local ethics committee (commission cantonale d’éthique de la recherche CCER de Genève). Coronavirus storage and procedures have been registered and validated by the Swiss Federal Office for the Environment (Bundesamt für Umwelt, BAFU) and the Swiss Federal Office of Public Health (Bundesamt für Gesundheit, BAG); Ecogen A203032-00, registered the 01-Sep-2020 for a duration of 5-years for the University of Zurich (Department of Molecular Life Sciences).

7. Results

7.1. Compound identification by image-based full infection-cycle screening using hCoV-229E-GFP

Host targeting with chemical compounds combined with full cycle image-based analyses is a powerful approach against viral infections, as recently demonstrated with the identification of the HIV protease inhibitor Nelfinavir blocking human adenovirus egress from infected cells (Georgi et al., 2020a,b). Here we used this approach to search for broadly effective coronavirus inhibitors. The screen with Huh7 cells infected with hCoV-229E-GFP was followed by high-throughput imaging as described (Yakimovich et al., 2015a; Georgi et al., 2020b). The infection assay scoring viral plaque formation was highly robust, as indicated by Z’ factors (Zhang et al., 1999) at or above 0.5, indicating excellent assay quality and consistent analysis pipelines (Fig. S1A).

We screened the EPFL BSF-repurposing compound collection, curated and corrected based on information made available by the Broad Institute (Corsello et al., 2017). The overall procedure is depicted in Fig. 1. The (continued)
5440 compounds for efficacy against hCoV-229E-GFP. This yielded 53 hits, which were tested for efficacy against hCoV-OC43 and SARS-CoV-2 in different cell lines, including Vero-E6, Huh7-ACE2, A549-ACE2 and HeLa-ACE2. In parallel, we determined the EC\textsubscript{50}, TC\textsubscript{50} and the ratio TC\textsubscript{50}/EC\textsubscript{50}, i.e., the quasi therapeutic index (TI). A selection of hits in advanced clinical state (approved or in phase I–III trials, anti-cancer, metabolism or anti-infectious agents) was used for validation to determine effective concentrations (EC\textsubscript{50}) and toxicity (TC\textsubscript{50}). The hit compounds were classified either as antivirals, anti-infectious agents, anti-cancer, metabolism or anti-inflammatory agents. We selected MB, MPA and POS for further validation. MB and POS effectively reduced the number of infection foci. MPA reduced the total GFP intensity, while Remdesivir showed complete infection inhibition of hCoV-229E-GFP at 0.33 μM (Fig. 2D).

7.2. Dose-response validation and hit extension to hCoV-OC43 and SARS-CoV-2

To assess the therapeutic potential of the 53 hit compounds EC\textsubscript{50} and TC\textsubscript{50} values were determined for hCoV-229E-GFP in Huh7 cells by conducting dose-response experiments with concentrations from 1.525 nM to 50 μM. The results are summarized in Table 1 and Table S3. Thirty nine compounds had an EC\textsubscript{50} < 2 μM and a therapeutic index (TI) of > 2, as determined by fluorescent focus formation (FFF). The slight discrepancy to the results obtained in the initial screen at 1.67 μM was due to additional parameters used for hit scoring in the original screen, including number of GFP positive cells, total GFP intensity and infection index, in addition to the number of fluorescent foci. Notably, the dose-response analyses yielded LY2090314 as the most potent compound, where the lowest concentration tested (1.525 nM) resulted in 41% reduction of 229E-GFP infection foci. We conservatively estimated of an EC50 of about 2 nM, and a TI of 31.7 μM. MB had an EC\textsubscript{50} of 1.43 μM, a TC\textsubscript{50} of 8.71 μM (TI of 6.09), and the EC\textsubscript{50} of MPA was estimated to 1.85 μM and TC\textsubscript{50} of 45.8 μM, resulting in a TI of 24.8 (Fig. 3A). POS had an EC\textsubscript{50} of about 2.5 μM and showed essentially no cell loss up to 50 μM. In addition, 39 compounds used at 1.75 μM proved to be effective and non-toxic against hCoV-OC43 infection of Huh7 cells (Table 1).

We next generated Huh7, human lung epithelial A549 and human cervical carcinoma HeLa cells expressing ACE2 by lentivirus transduction (Fig. S2). These ACE2-transduced cells as well as African green monkey kidney epithelial Vero E6 cells were susceptible to SARS-CoV-2 (Fig. 3B and Table 1). Eleven compounds were effective and non-toxic against hCoV-OC43 infection of Huh7 cells (Table S3). Eleven compounds were effective in two or more cell lines against SARS-CoV-2, and two of them in all cell lines, namely POS and Ro 48–8071. The preclinical compound Ro 48–8071 had the best hit profile regarding effectiveness in all four cell lines against SARS-CoV-2, and hCoV-OC43. Ro 48–8071 affects oxidosqualene cyclase in cholesterol biosynthesis (Maloney et al., 2015a). In addition, the launched anti-fungal compound POS showed a similar profile, but did not meet the dose-response criterion with an EC\textsubscript{50} of 4.20 μM against hCoV-229E-GFP infection (Fig. 3A). We did, however, not observe any toxicity effects for POS up to 50 μM. MPA, Thonzonium bromide and MLN4924 were effective against SARS-CoV-2 in three cell lines, and also inhibited hCoV-OC43. Notably, the number of compounds effective against both hCoV-229E-GFP and hCoV-OC43 was much higher than those effective in hCoV-229E-GFP, and high-throughput imaging (Fig. 2A). This allowed us to extract image analysis parameters, including total cell count, infected cell count, total GFP intensity and number of infection foci (plaques) (see also Fig. S1A). Two subsequent validation filters were applied with hCoV-OC43 infection of Huh7 cells, and SARS-CoV-2 infection of Vero E6, Huh7 expressing the angiotensin-converting enzyme 2 (ACE2), HeLa-ACE2 and A549-ACE2 cell lines. A set of selected drugs was then tested in nasal and bronchial HAECC. These procedures identified MPA, MB and POS to be effective against 229E-GFP, OC-43 and SARS-CoV-2 infections, inhibiting virus accumulation and cell-cell transmission. These parameters were normalized per-plate to the mean value of all negative control wells. A compound was classified as hit inhibiting infection if a Z score of < 3 for all of these normalized infection parameters was obtained, that is, if its value was less than the mean of the negative controls minus three standard deviations (Fig. 2B)
against SARS-CoV-2. This effect did not seem to be cell-line dependent, as for example Huh7-ACE2 used for SARS-CoV-2 are derived from Huh7 cells used with hCoV-229E-GFP and hCoV-229E. It is unlikely though that temperature differences in infection (37 °C versus 33.5 °C) affected drug effectiveness against SARS-CoV-2. In summary, the cell line screens with the endemic coronaviruses 229E, OC43 and the pandemic SARS-CoV-2 uncovered six clinically launched compounds, MB, MPA, POS and R788-Fostamatinib, and the topical compounds Thonzonium bromide, a monocationic surfactant with bacteriocidal effects (Chan et al., 2012), and Cetylpyridinium used in mouth wash formulations (Pitten and Kramer, 2001), which inhibited all three viruses in the micromolar concentration range, similar to Remdesivir (Tables 1 and 2, Table S3). In the following, we focussed on the systemic compounds.

7.3. MB and Remdesivir synergize against CoV infection and block the accumulation of viral (+)RNA in cells

We first explored if the top systemic compounds MB, MPA and POS had synergistic effects against hCoV-229E-GFP in the full cycle fluorescent foci formation assay. Since MPA and POS did not show synergistic effects with Remdesivir on hCoV-229E-GFP infection of Huh7 cells, we focussed on MB. Striking synergy effects occurred against hCoV-229E-GFP in human hepatoma Huh7 cells at 500 nM MB in combination with 50 nM Remdesivir, yielding a BLISS synergy score of 50 (Fig. 4A and B). These effects were similar in human lung carcinoma cells (H1299) with MB at 5 μM and Remdesivir at 250 nM, yielding a BLISS synergy score of 31.3 (Fig. 4B). The results indicate that suitable concentrations of Remdesivir and MB enhance anti-coronavirus effects suggesting that Remdesivir and MB affect infection by independent mechanisms.

To address the anti-viral mechanisms of MB, MPA and POS, we developed a procedure to score intracellular RNA of OC-43 and SARS-CoV-2 at MOI 1 in Huh7 and Huh7-ACE2 cells by fluorescence in situ hybridization using probes against the (+)RNA strand in ORF1a. The procedure was adapted from previous work with adenovirus and rhinovirus (Yakimovich et al., 2015b; Suomalainen et al., 2020; Suomalainen and Greber, 2021). The infection phenotype was scored in MB, MPA, POS and Remdesivir-treated cells by automated measurement of fluorescent puncta representing single viral RNA molecules. At 2 h pi, 80% or more of the cells contained at least one discernible fluorescent punctum of OC43 (Fig. 4C) or SARS-CoV-2 (Fig. 4D), akin to DMSO control treated cells. While control cells had abundant intracellular viral (+)RNA, MB, POS and Remdesivir-treated cells showed essentially no indications of increased viral RNA. This was contrasted by...
containing replicated viral RNA. The levels of viral RNA-free cells upon MPA-treated cells showing an intermediate phenotype, with some cells against SARS-CoV-2 (Wuhan).

There is a good agreement between the original screen, 229E-GFP dose-response cell lines. Ticks mark compounds qualifying as hits in the respective experiment.

Table 1 Validation of the 53 top hits from the initial full cycle infection screen.

| Compound          | 229E-GFP | OC43 | SARS-CoV-2 | SARS-CoV-2 | SARS-CoV-2 | SARS-CoV-2 |
|-------------------|----------|------|------------|------------|------------|------------|
|                   |          |      |            |            |            |            |
| Compounds         |          |      |            |            |            |            |
|                   |          |      |            |            |            |            |
| A0001             | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Fostamatinib      | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Methylene Blue    | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| MLN4924           | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Mycophenolic acid | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| OTSSP167          | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Posaconazole      | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Ro 48-8071        | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Abafungin         | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Arivacin          | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Afrometin         | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Anisomycin        | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| APY0201           | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| ATV928            | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| AZD8588           | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| AZD5438           | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Betulinic acid    | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Cerdulatinib      | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Cetylpyridinium    | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| CHIR-124          | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| CHIR-9801        | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| CUDC-907          | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Cyclopiazonic-acid| ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Eprinomectin      | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| FHC35             | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Geldanamycin      | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| GPP-78            | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| GSK 3 Inhibitor IX| ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| GZD824            | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Huavuconazole     | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| JTE-013           | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| LE-135            | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Lomefloxacin      | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| L12090314         | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Methenazol        | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Oxapiron          | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Pelitinib         | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| PF-04457845       | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| FF-3845           | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| PFK-015           | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| RAF265            | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Ravaconazole      | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| SB225002          | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| SB-505124         | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Tanaprost        | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| TCS-21311         | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| Thononzium bromide| ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| TRO 19622         | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| UK-5099           | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |
| VU29              | ✔         | ✔     | ✔           | ✔           | ✔           | ✔           |

All compounds identified as hits in the original screen are listed. The compounds highlighted in bold at the top of the table are clinically launched. Columns represent different validation experiments with the corresponding viruses and cell lines. Ticks mark compounds qualifying as hits in the respective experiment. There is a good agreement between the original screen, 229E-GFP dose-response (D-R) and hCoV-OC43 in Huh7 cells with fewer compounds also being effective against SARS-CoV-2 (Wuhan).

MPA-treated cells showing an intermediate phenotype, with some cells containing replicated viral RNA. The levels of viral RNA-free cells upon MB, POS or Remdesivir treatment remained constant or increased slightly compared to 2 h pi (Fig. 4C and D, grey bars), suggesting that these drugs lead to elimination of incoming viral RNA from cells over time. We conclude that MB, MPA and POS block viral (-)RNA enrichment in infected cells, and MPA has somewhat less pronounced effects.

7.4. MB, MPA and POS inhibit SARS-CoV-2 infection of HAEEC

Based on the broad antiviral effects of MB, MPA and POS in cell cultures, we tested these compounds together with another systemic launched compound hit R788-Fostamatinib, and four preclinical compounds in SARS-CoV-2 infections of well differentiated human nasal or bronchial airway cells grown at air-liquid interface (Epithelix, MucilAir™). Cells were either pre-treated or post-treated one day after apical inoculation of SARS-CoV-2 using low micromolar concentrations of compounds. The preclinical compounds comprised the broad kinase inhibitor OTSSP167 (Zhang et al., 2018), the vitamin E metabolite A0001 (α-tocopheryl-quinone) (Hawi et al., 2012), the NAE (Nedd8 activating enzyme) inhibitor MLN4924 (Ponvedestat) (Soucy et al., 2009a) and the oxidosqualene cyclase inhibitor Ro48-8071 involved in cholesterol biosynthesis (Matone et al., 2015b). However, none of the four preclinical compounds tested was considered further. OTSSP167 and A0001 lacked anti-viral activity, while MLN4924 and Ro48-8071 were toxic in HAEEC (Table S4). Remarkably, R788-Fostamatinib exhibited no consistent anti-viral effects on SARS-CoV-2 titer release in the apical milieu at 3.3 or 10 μM but gave rise to changes in HAEEC morphology, and therefore was not further considered.

In contrast to Fostamatinib, MB, MPA, and POS-treated HAEEC remained morphologically unchanged in both pre- and post-exposure settings, akin to Remdesivir-treated cells, the latter as previously reported (Pizzorno et al., 2020). MB, MPA and POS treated inserts displayed robust ciliary beating akin to uninfected cells, whereas exposure to a toxic concentration of MLN4924 strongly impaired ciliary movement (Fig. S3F, M at 5 μM), MPA and POS treatments did not affect ciliary function (Fig. S3F, M but gave rise to changes in HAEEC morphology, and therefore was not further considered.

We next tested the effects of MB, MPA and POS on SARS-CoV-2 variants of concern. These variants have higher human to human transmission and exhibit reduced susceptibility against antibodies from mRNA- and AdV vector-immunized vaccinees. While POS showed detectable albeit little efficacy against the alpha (B1.1.7), beta (B1.351), gamma (P.1) and delta (B.1.617.2) variants of SARS-CoV-2 in post exposure settings with nasal HAEEC, MB and MPA were strongly effective, similarly as against SARS-CoV-2 ‘Wuhan’ (Fig. 6, Fig. S6, Fig. S7). Apical release of viral genomes was not reduced in post exposure
treatments with either MB, MPA or POS, in contrast to Remdesivir, consistent with the findings in SARS-CoV-2 ‘Wuhan’ infections (Figs. S3B and D, Suppl Tab 4, Figs. S6 and S7). All the virus TCID$_{50}$ titers and genome copy numbers are listed in Table S4. Together, our results demonstrate broad efficacy of MB and MPA and somewhat lesser effects by POS against seven human coronaviruses, the SARS-CoV-2 ‘Wuhan’ strain, the alpha, beta, gamma, and delta variants as well as the endemic CoV viruses 229E and OC43, by a mechanism distinct from Remdesivir.

**8. Discussion**

Individuals suffering from COVID-19 are in need of acute medical treatment with broadly available safe and effective antivirals. In addition, the zoonotic and anthropogenic transmission of coronaviruses from animals to humans and from humans to animals (Gorman et al., 2018; Oreshkova et al., 2020) may demand the treatment of livestock and pets with compounds against coronaviruses to shrink viral reservoirs. Hence, broad acting anti-virals at affordable cost will be required, a demand, which may be fulfilled by repurposing small chemical compounds targeting the host. Host targeting is likely less prone to raise viral resistance, unlike direct virus targeting, as in case of Remdesivir or the mutator nucleoside MK-4482/EIDD-2821 (Cox et al., 2021; Agostini et al., 2018; Lo et al., 2020; Sheahan et al., 2020). Notably, Remdesivir leads to stalling of the coronavirus RNA-dependent RNA polymerase and has a conserved mode of inhibition across different viruses, where a single point mutation in the Ebolavirus polymerase mediates drug resistance.
resistance (Lo et al., 2020; Yin et al., 2020). De novo development of antivirals is a lengthy and costly process and insufficient to resolve the current crisis in short terms (Ward et al., 2015). Our large scale drug repurposing screen identified broadly acting clinically approved small molecular weight compounds. We took advantage of the curated and mass spectrometry-validated BSF library composed of 5440 distinct chemical compounds, most of which have been approved for human use in nonviral indications or in clinical development. We harnessed the power of fluorescence imaging assessing the full virus replication cycle from entry to egress and spread to neighboring cells. This procedure previously identified Nelfinavir as an adenovirus egress inhibitor, notably in contrast to a previous publication earmarking it as ineffective against adenovirus in PCR-based virus replication assays (Georgi et al., 2020b; Gantt et al., 2011). To the best of our knowledge, none of the drug screening projects carried out by others has used our collection of compounds with a full cycle image-based assay. The coronavirus screen developed here scored fluorescent focus formation of hCoV-229E infection, and independently reduce the intracellular load of replicated OC43 and SARS-CoV-2 plus strand RNA, alongside with POS and MPA. A) Overview of a 96-well plate infected with hCoV-229E-GFP and treated with combinations of remdesivir (1 nM–250 nM) and MB (100 nM–1 μM) in 2-, 4-, 5-, 10-fold serial dilutions. B) Quantification of plaque counts in presence of the indicated concentrations of MB and remdesivir in Huh7 (left panel) and H1299 (right panel). C) Huh7 cells were infected with OC43 for 2 or 24h in presence of remdesivir (1 μM), POS (10 μM), MB (2 μM) or MPA (2 μM). Cells were fixed and stained against OC43 ORF1a (+)RNA using RNA FISH with branched DNA signal amplification. Nuclei were stained with DAPI. OC43 (+)RNA dots were segmented and quantified per cell. Infected cells contained at least one viral RNA per cell, replicating cells were defined as containing more than seventy-five viral RNAs per cell, i.e., the maximal detection limit for counting individual mRNA puncta in infected Huh7 cells (see similar numbers for A549 cells in, Suomalainen et al., 2020). Images are maximum projections. Scale bar, 10 μm. B) Quantification of plaque counts in presence of the indicated concentrations of MB and remdesivir in H1299 (left panel) and Huh7 (right panel). C) Huh7-ACE2 cells were infected with SARS-CoV-2 for 2 or 8h in presence of remdesivir (1 μM), POS (10 μM), MB (2 μM) or MPA (2 μM). Cells were fixed, stained against SARS-CoV-2 ORF1a (+)RNA and processed as described in (C). Images are maximum projections. Scale bar, 10 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Daly et al., 2020). Hence, the compounds that we identified likely target host functions in virus progeny formation, egress from infected cells or transmission to neighboring cells. We confirmed this notion for MB, MPA and POS, which did not block the uptake of viral RNA but reduced the levels of replicated viral genomes in the infected cells.

8.1. MB is a broad antiviral against coronavirus infections

Previous studies had suggested that MB inhibits SARS-CoV2 entry in Vero E6 cells (Gendrot et al., 2020), or SARS-CoV-2 S-protein pseudotyped viruses in HEK-ACE2 cells (Bojadzic et al., 2020). This contrasts our RNA FISH staining of the incoming viral RNA, which showed no effect of MB, MPA, or Remdesivir on the amount of intracellular virus genome for SARS-CoV-2 and OC43 at 2h pi. In addition, MB, MPA and Remdesivir did not inhibit the virus or genome equivalent release from HAEEC in pre-exposure treatments at 1dpi, although POS had an inhibitory effect. This strongly argues for post-entry mode-of-action of MB, MPA and Remdesivir, the latter being a defined RdRP inhibitor.

MB has long been used in humans against malaria and methemoglobinemia (Walter-Sack et al., 2009; Schirmer et al., 2003; Patnaik et al., 2014). Many trials have employed it as a placebo agent with an extremely high safety profile. Yet, MB is not inert, it is an oxido-reductive thiazine dye cycling between the oxidized form (MB) and the reduced form leuco-MB (L-MB) (Buchholz et al., 2008). The reduction occurs through cellular flavo oxido-reductases, such as glutathione reductase, thioredoxin reductase or the mitochondrial membrane associated dihydrolipoamide dehydrogenase at the expense of nicotinamide adenine dinucleotide phosphate (NADPH). L-MB readily auto-oxidates to MB, a process which consumes molecular oxygen and yields hydrogen peroxide, a strong oxidizing agent. The oxidizing conditions trigger the expression of a range of response genes, most notably the transcription factor Nrf2 (nuclear factor erythroid 2-related factor). Nrf2 interlinks with a range of cellular stress and homeostasis pathways, such as the oxidative and xenobiotic stress response, mitochondrial respiration, the UPR in the endoplasmic reticulum and autophagy (Tonelli et al., 2018; Prasad and Greber, 2021). It is thus conceivable that the overexpression of Nrf2 has negative effects on SARS-CoV-2 infection. In support of this notion, Nrf2 mediated gene expression was found to be suppressed in biopsies obtained from COVID-19 patients (Olagnier et al., 2020).

Moreover, another top performer in our screen, GPP-78 targets nicotinamide phosphoribosyltransferase, a crucial enzyme in the NAD salvage/recycling pathway (Khan et al., 2007), lending further support to the importance of redox control in coronavirus infection.

Intriguingly, our data reveal a discrepancy between infectious progeny virus production and viral genome copy numbers released from the HAEEC. In control cells, SARS-CoV-2 progeny peaked at 3–4 d pi and declined by 2–3 logs 8 d pi, while the genome copy numbers remained constant after day 4 of infection (Fig. S3). By using two distinct pairs of PCR primers, one for the RNA polymerase subunit Nsp12 and the other one for the M-gene, we excluded that this discrepancy is an artifact to subgenomic replicons known to comprise the M-gene. Importantly, the discrepancy was in perfect agreement with a previous study quantifying the N-gene RNA (Robinot et al., 2021). Since infected HAEEC cells treated with MB (and also MPA and to a lesser extent POS) strongly reduced the amounts of infectious

Fig. 5. MB, MPA and POS inhibit SARS-CoV-2 infection of nasal HAEEC. Antiviral effects of drug treatments represented as means ± SEM of two independent replicates. Baseline levels represent the apical means ± SEM of virus titer from the DMSO control sample at 1d pi. The same DMSO control was used for the pre- and post-exposure treatments. A) Nasal HAEEC grown at ALI were inoculated apically with 1000 FFU of SARS-CoV2 Wuhan (day 0), and treated with drugs in the basolateral medium in a pre-infection regimen, starting at 2h prior to virus inoculation (left) or in a post-infection regimen starting at 1 d pi (right). MB and MPA were administrated daily until day 3 at 10 μM or until day 6 at 1 μM. B) POS (5 and 20 μM) was administrated daily until day 8. Remdesivir (10 μM) and DMSO served respectively as positive and negative drug treatment control and were administrated daily until day 8. SARS-CoV-2 released to the apical side was collected daily by apical washing and quantified by virus TCID50 titration.
virus but not the genome copy numbers, we suggest that MB and MPA block hCoV progeny formation and apical release of virions. Since MB, MPA and POS reduced the intracellular viral (+)RNA levels in Huh7 cells, these compounds may induce intracellular degradation or export rather than blocking synthesis of viral RNA. In contrast, the viral RNA polymerase inhibitor Remdesivir blocked the synthesis of viral RNA, as demonstrated by both intracellular and extracellular viral RNA measurements. This argues that MB, MPA and POS act by a distinct mode of action compared to Remdesivir. This contention is supported by our observation that MB and Remdesivir synergize against hCoV cell culture infection in the range of 0.5–5 μM MB and 50–500 nM Remdesivir. These results encourage interventional trials against COVID-19 combining two FDA-approved drugs, MB and Remdesivir. The former is already given intravenous (i.v., or per oral) for the treatment of pediatric and adult patients with acquired methemoglobinemia, and the latter for treatment of early COVID-19, while it is largely ineffective at late stages of coronavirus disease (Ohl et al., 2021). Pharmacokinetics data from patients show that MB is well absorbed from the GI tract and reaches similar blood concentration levels as upon i.v. administration, although its organ distribution differs compared to i.v. administration in rats (Peter et al., 2000). For instance, 2 mg/kg dosage (recommended for treatment of methemoglobinemia) yields plasma levels of about 0.1 μM with a half life of 5–6h. Remarkably, a COVID-19 phase II clinical trial at 1 mg/kg per oral (every 8 h for two days, and then twice daily for the following 12 days) reported a 50% mortality reduction of severe COVID-19 cases, as well as increased blood oxygenation and respiratory rate (Hamidi-Alamdari et al., 2021). Clinical trials comparing regular as well as reduced dosages of MB and Remdesivir may be warranted (Beigel et al., 2020a; Hamidi-Alamdari et al., 2021). Endpoints may include survival and blood oxygenation levels, both of which are expected to be enhanced by the combination treatment due to the anti-viral effects of both agents and the potency of MB to treat methemoglobinemia in patients resistant to oxygen therapy.

8.2. A two-pronged action of MPA - anti-viral and anti-inflammatory

Our screen and follow-up experiments identified MPA as a broad antiviral inhibitor. MPA is a non-competitive inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH) involved in guanine biosynthesis (Hedstrom, 2009). IMPDH interacts with and supports SARS-CoV nonstructural protein 14 (Nsp14), a guanine-N7-methyl-transferase implicated in virus replication and transcription (Chen et al., 2009). In addition, MPA leads to a reduction in the levels of the furin protease in human pluripotent stem cell derived lung organoids, and inhibits the entry of S-glycoprotein pseudotyped vesicular stomatitis particles (Han et al., 2021). Furin has a key role in viral pathogenesis and dissemination, and is required for the limited proteolysis of the SARS-CoV-2 S-protein, and S-protein engagement with the neuropilin-1 receptor and virus
MPSA is also a weak immunosuppressant used in transplant patients as Mycophenolate Mofetil (MMF, Myfortic®, Novartis) for reduction of transplant rejection risk (Han et al., 2021). MMF is readily converted to MPA by cellular esterases, and orally or intravenously broadly bioavailable at low side effects. And MPA inhibits SARS-CoV-2 infection of humanized mice and human lung organoids (Park, 2011). An initial clinical case reported that a COVID-19 patient affected by autoimmune blistering disease (ABD) during immunosuppressive treatment, i.e., azathioprine, was treated with MMF, and experienced only a mild form of COVID-19, without pulmonary complications or detrimental effects (Di Altabrandi et al., 2020; Balestri et al., 2020). Notably, SARS-CoV-2 leads to a massive destruction of host mRNAs (Banerjee et al., 2020), except transcripts encoding the NFκB pathway, a situation, which leads to cytokine storms in COVID-19 patients (Mehta et al., 2020).

Given the immunosuppressive anti-inflammatory effects of MPA, we suggest a two-pronged modality of MPA towards treating COVID-19. One is an antiviral action at moderate concentration to reduce systemic disease, and the other one is anti-inflammatory. For clinical applications, we envision a low dosage modality of MPA/MMF in mild COVID-19 cases (0.1 g, twice daily), and a higher dosage in mid and severe COVID-19 cases (1.5 g, twice daily), resulting in plasma concentrations of 1–15 μg/ml MPA/MMF (approximately 2–30 μM) (Staatz and Tett, 2007). The precise dosage would have to be tuned individually as MPA/MMF exhibits considerable within-subject variability of 9–17 h half life. This regimen goes along with the notions that 1) moderate concentrations of MPA/MMF (1–3 μM) already exhibit noticeable anti-viral effects, and 2) higher doses (10 μM) have well described immunosuppressive effects in organ transplant patients at risk reduction of transplant rejection. Anti-inflammatory and immuno-suppressive agents may be beneficial to severe COVID-19 cases as shown with corticosteroid treatment (Neurath, 2021; Coperchini et al., 2020) albeit with variable outcomes and requiring close patient monitoring (Beigel et al., 2020b; Cain and CIDlowski, 2020).

In contrast to corticosteroids, MPA/MMF has well characterized distinct anti-inflammatory effects. For example, the reversible inhibition of IMPDH results in blockage of de novo guanosine synthesis, which suppresses the proliferation of T and B lymphocytes (Rugui et al., 1991). Hence, MPA/MMF may best be applied for days rather than weeks. B and T cells are largely devoid of salvage pathways for the synthesis of guanosine, and hence are particularly susceptible to MPA. MPA/MMF treatment leads to a reduction in mRNAs encoding pro-inflammatory cytokines, such as TNF-α, IL-6 & IL-1b (Lv et al., 2015; Huang et al., 2020). Our screen revealed several additional launched compounds already described for their potential to treat COVID-19, including Fostamatinib, Eprinomectin and Betulinic acid. Fostamatinib is an FDA approved Syk tyrosine kinase inhibitor for the treatment of chronic immune thrombocytopenia (Kost-Alimova et al., 2020), and in a phase 4 clinical phase trial against COVID-19 (NCT04629703). Although Fostamatinib inhibited SARS-CoV-2 infection of cultured human cells and African green monkey Vero cells, we did not pursue this compound further due to morphological alterations in the HAEEC, including outgrowth of fibroblasts. Likewise, we did not follow up on Eprinomectin, a benzodiazepine receptor agonist with anti-parasitic activity but unknown mode-of-action against SARS-CoV-2 by dysregulating the oxidative state of the cell and enhancement of Nrf2.

### 8.5. Other compounds

Our screen revealed several additional launched compounds already described for their potential to treat COVID-19, including Postamatinib, Eprinomectin and Betulinic acid. Postamatinib is an FDA approved Syk tyrosine kinase inhibitor for the treatment of chronic immune thrombocytopenia (Kost-Alimova et al., 2020), and in a phase 3 clinical phase trial against COVID-19 (NCT04629703). Although Postamatinib inhibited SARS-CoV-2 infection of cultured human cells and African green monkey Vero cells, we did not pursue this compound further due to morphological alterations in the HAEEC, including outgrowth of fibroblasts. Likewise, we did not follow up on Eprinomectin, a benzodiazepine receptor agonist with anti-parasitic activity but unknown mode-of-action, though approved for veterinary use in horses, cattle and cats, akin to other avermectins (El-Saber Batiha et al., 2020). We refrained from further investigating Betulinic acid, a pentacyclic triterpenoid with attributed anti-retroviral, anti-malarial, and anti-inflammatory properties but also anti-proliferative and apoptotic effects (Verma et al., 2020).

Intriguingly, our high-throughput screen with 229E-GFP revealed a cluster of five distinct compounds targeting glycogen synthase kinase 3 (GSK-3), namely LY2090314 (Atkinson et al., 2015), which was the most potent compound identified in our hCoV-229E-GFP (EC50 2 nM), GSK-3 inhibitor IX (Meijer et al., 2003), TCS-21511 (Thoma et al., 2011), AZD2858 (Marsell et al., 2012) and CHIR-99014 (Ring et al., 2003). GSK-3 phosphorylates a variety of proteins in glycogen metabolism, innate immunity and apoptosis (Jope and Johnson, 2004), and some of its inhibitors are approved to treat cancer, inflammation, Alzheimer’s, and diabetes (Augello et al., 2020). GSK-3 inhibitors have also been proposed for SARS-CoV-2 treatment, based on the notion that GSK-3 is implicated in phosphorylation of SARS-CoV-2 N-protein (Liu et al., 2021). Unfortunately, none of the GSK-3 inhibitors identified in our screen translated antiviral effects to SARS-CoV-2 infections of HAEEC.

### 8.4. Repurposing SARS-CoV-2 inhibitors in clinical development

One of our strongest hits in the cell culture screens was MLN4924 (Pevonedistat) with an excellent dose-response profile against hCoV-229E-GFP (EC50 30 nM; EC90 40.39 μM) and considerable inhibition of SARS-CoV-2. It is a promising candidate in retinoblastoma therapy (Aubry et al., 2020), but unfortunately exhibited toxicity in our HAEEC experiments at low micromolar concentrations (Table S4). Nonetheless, MLN4924 is an interesting tool compound in cell culture, where it targets the Nedd8 activating enzyme (Nae) with potential anti-neoplastic activity (Soucy et al., 2009b; Lan et al., 2016), and prevents the degradation of Nrf2 (Zhao et al., 2014). Possibly, MLN4924 and MB have a similar mode-of-action against SARS-CoV-2 by dysregulating the oxidative state of the cell and enhancement of Nrf2.
In conclusion, our image-based, high content, full cycle screen against human coronavirus infection provides a high quality hit list of clinical and preclinical compounds, including five clinically launched drugs, of which MB, MPA and POS were found to inhibit virus production in HAECC. Two topical agents, thonzonium bromide, a monocationic surfactant with bacteriocidal effects (Chan et al., 2012), and the mouthwash component Cetylpyridinium scored in coronavirus cell culture infections, and may represent additional repurposing candidates for future analyses.

8.6. Perspective

Our top compounds are effective against SARS-CoV-2 Wuhan strain as well as four variants of concern, alpha, beta, gamma, and delta. These variants likely evolved in humans since December 2019, indicating that evolution and turnover of the circulating SARS-CoV-2 do not affect the efficacy of our inhibitors in human explant cell cultures. This is distinct from inhibitors targeting the virus directly, which the virus rapidly evades, for example favipiravir. Favipiravir is an RNA mutagen with antiviral effects (Delang et al., 2018) approved in Japan to treat pandemic influenza virus infections. It has anti-viral effects against SARS-CoV-2 in hamsters (Driouch et al., 2021) and is in clinical trials against COVID-19 (Joshi et al., 2021). A recent high-throughput computational protein design protocol identified mutational hotspots in the SARS-CoV-2 RNA polymerase confering favipiravir resistance, and remarkably some of these mutations already exist in SARS-CoV-2 genomes circulating in humans (Padhi et al., 2021; Greber, 2021). This implies that direct anti-viral agents readily face drug-resistant viruses, even before treatment, and likely have limited therapeutic effects. We surmise that host targeting anti-virals, such as the compounds identified in this study will have a higher fitness cost for virus to evade than direct anti-viral agents, akin to a recent study on chemical evolution of rhinovirus (Murer et al., 2021).

Author contributions

UFG initiated, conceived and supervised the project. LM, RV, NM, LY, DS, AGG, AP, DO, MB, FG, MS, FK, GT, UFG designed, carried out or analyzed experiments. LM, RV provided data visualization. VA, LM provided data curation and software. LM, RV, UFG wrote the paper. GT, UFG acquired funding. All authors read and approved the manuscript.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: UFG has been a consultant and stock owner in 3V-Biosciences (now 3V-Bio). UFG has been a consultant and stock owner in 3V-Biosciences (now 3V-Bio). UFG has been a consultant and stock owner in 3V-Biosciences (now 3V-Bio). UFG has been a consultant and stock owner in 3V-Biosciences (now 3V-Bio). UFG has been a consultant and stock owner in 3V-Biosciences (now 3V-Bio). UFG has been a consultant and stock owner in 3V-Biosciences (now 3V-Bio).

Appendix A. Supplementary data

Supplementary data to this article can be found at https://doi.org/10.1016/j.crviro.2022.100019.

References

Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Shethan, T.P., Lu, X., et al., 2018. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9 (2), e00221–18.
Ashburner, T.T., Thor, K.B., 2004. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3 (8), 673–683.
Atkinson, J.M., Rank, K.B., Zeng, Y., Capen, A., Yadav, V., Manro, J.R., et al., 2015. Activating the Wnt/j-catenin pathway for the treatment of melanoma-application of LY2090314, a novel selective inhibitor of glycosy synthase kinase-3. PloS One 10 (4), e0125026.
Aubry, A., Yu, T., Bremner, R., 2020. Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy. Cell Death Discov. 6 (1), 1–12.
Augello, G., Emma, M.R., Cusimano, A., Azzolina, A., Montalto, G., McBeyure, J.A., et al., 2020. The role of GSK-3 in cancer immunotherapy: GSK-3 inhibitors as a new frontier in cancer treatment. Cells 9 (6), 1427.
Baden, L.R., El Sahly, H.M., Eskin, B., Koloff, K., Frey, S., Novak, R., et al., 2021. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384 (5), 403–416.
Bakowski, M.A., Beutler, N., Wolf, K.C., Kirkpatrick, M.G., Chen, E., Nguyen, T.H., et al., 2021. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nat. Commun. 12 (1), 3309.
Balestri, R., Roeh, G., Cereselli, D.R., 2020. Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus. J. Eur. Acad. Dermatol. Venereol. 34 (9), e435–e436, PMC7267403. https://doi.org/10.1111/jdv.16578.
Banerjee, A.K., Blanco, M.R., Bruce, E.A., Honom, D.D., Chen, L.M., Chow, A., et al., 2020. SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses. Cell 183 (5), 1325–1339 e21.
Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., et al., 2020a. Remdesivir for the treatment of Covid-19: final report. N. Engl. J. Med. 383 (19), 1813–1820.
Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., et al., 2020b. Remdesivir for the treatment of Covid-19. N. Engl. J. Med. 383 (19), 1813–1820.
Belov, G.A., Nair, V., Hansen, B.T., Hoyt, F.H., Fischer, E.R., Ehrenfeld, E., 2012. Complex dynamic development of poliovirus membranous replication complexes. J. Virol. 86 (1), 302–312.
Bojadzic, D., Alcazar, O., Buchwald, P., 2020. Methylene blue inhibits the SARS-CoV-2 spike-ACE2 protein-protein interaction-a mechanism that can contribute to its antiviral activity against COVID-19. Front. Pharmacol. 11, 600372.
Buchholz, K., Schirmer, R.H., Ebel, J.K., Akoachere, M.B., Dandekar, T., Becker, K., et al., 2020. Interactions of mycophenyl blue with human di sulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob. Agents Chemother. 52 (1), 1–11.
Chan, C.Y., Prudom, C., Raines, S.M., Charkhzarrin, S., Melman, S.D., De Haro, L.P., et al., 2020. Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether molecules. Sci. Rep. 10 (1), 752–756.
Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S.C., Di Napoli, R., 2021. Features, clinicals, and treatment of COVID-19 interventions. Nat. Commun. 12 (1), 3309.
Cervantes-Barragan, L., Züst, R., Maier, R., Sierro, S., Janda, J., Levy, F., et al., 2010. Activating the Wnt/j-catenin pathway for the treatment of melanoma-application of LY2090314, a novel selective inhibitor of glycosy synthase kinase-3. PloS One 10 (4), e0125026.
Cox, R.M., Wolf, J.D., Plemper, R.K., 2021. Therapeutically administered ribonucleoside activators for COVID-19. J. Med. Chem. 64 (14), 8561–8568.
Cottee-Patton, L., Otis, R., Pedra, L.D., Djennatian, M., Franz, J., Kuivainen, S., et al., 2020. Neurophilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370 (6518), 751–756.
Cotzev, K., Malik, Z., Dhabhar, S.F., 2017. Cardiovascular reprogramming by exercise: the role of the Wnt signaling pathway. Front. Physiol. 8, 249.
Crepinelli, F., Chiavazzo, L., Allegri, M., Ricci, S., Fatimo, S., Salvatore, C., et al., 2017. RNAi and CRISPR-Cas9 based therapy for melanoma. N. Engl. J. Med. 377 (26), 2526–2538.
Creyts, K., Walker, S.C., Samuels, R.J., 2021. SARS-CoV-2 vaccines. JAMA 325 (13), 1318–1320.
